Ardelyx up 13% on quarterly results beat

seekingalpha05-03

Ardelyx (NASDAQ:ARDX), aided by strong sales of its chronic kidney disease drug Xphozah (tenapanor) in its first full quarter on the market, beat 2024 Q1 expectations on the top and bottom line. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432957057?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499205246/image_499205246.jpg","is_english":true,"pubTime":"2024-05-03 05:38","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2432957057","market":"fut","top_or_hot":-1,"title":"Ardelyx up 13% on quarterly results beat","media":"seekingalpha","content":"<div>\n<p>Ardelyx (NASDAQ:ARDX), aided by strong sales of its chronic kidney disease drug Xphozah (tenapanor) in its first full quarter on the market, beat 2024 Q1 expectations on the top and bottom line. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4099291-ardelyx-up-13-quarterly-results-beat\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx up 13% on quarterly results beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx up 13% on quarterly results beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 05:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4099291-ardelyx-up-13-quarterly-results-beat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx (NASDAQ:ARDX), aided by strong sales of its chronic kidney disease drug Xphozah (tenapanor) in its first full quarter on the market, beat 2024 Q1 expectations on the top and bottom line. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4099291-ardelyx-up-13-quarterly-results-beat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"https://seekingalpha.com/news/4099291-ardelyx-up-13-quarterly-results-beat","article_id":"2432957057","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/499205246/image_499205246.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432957057","pubTimestamp":1714685914,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Ardelyx , aided by strong sales of its chronic kidney disease drug Xphozah  in its first full quarter on the market, beat 2024 Q1 expectations on the top and bottom line. Xphozah, which won U.S. FDA approval in October 2023, brought in $15.2M in the quarter.  The company's other marketed treatment, Ibsrela , approved for irritable bowel syndrome with constipation, had revenue of ~$28.4M, compared to ~$11.4M in the year-ago period. Ardelyx's  net loss narrowed ~1% year over year to ~$26.5M. Net loss per share, basic and diluted, improved to -$0.11 from -$0.13. Shares are up ~13% in after-hours trading Thursday.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx","BK4139":"生物科技"},"translate_title":"Ardelyx股价上涨13%，超过季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Ardelyx (NASDAQ:ARDX), aided by strong sales of its chronic kidney disease drug Xphozah (tenapanor) in its first full quarter on the market, beat 2024 Q1 expectations on the top and bottom line. Xphozah, which won U.S. FDA approval in October 2023, brought in $15.2M in the quarter.  The company's other marketed treatment, Ibsrela (tenapanor), approved for irritable bowel syndrome with constipation, had revenue of ~$28.4M, compared to ~$11.4M in the year-ago period. Ardelyx's (ARDX) net loss narrowed ~1% year over year to ~$26.5M. Net loss per share, basic and diluted, improved to -$0.11 from -$0.13. Shares are up ~13% in after-hours trading Thursday.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432957057"}